Clinical Trials on Sexually Transmitted Diseases

Total 383664 results

National Institute of Allergy and Infectious Diseases...

Completed

Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth

HIV Infections

Thailand
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Pasteur Merieux Connaught

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Glaxo Wellcome

Completed

Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3

HIV Infections

United States
Medical College of Wisconsin
National Institute of Mental Health (NIMH)

Enrolling by invitation

HIV Prevention Among At-risk Latinos in the Heartland

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Hoffmann-La Roche

Completed

A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
VIMRx Pharmaceuticals

Completed

A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.

Completed

Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Harvard School of Public Health (HSPH)

Completed

Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

HIV Infections

Botswana
National Institute of Allergy and Infectious Diseases...
Applied Immunesciences

Completed

A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

HIV Infections

United States, Brazil, South Africa
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women

HIV Infections
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

HIV Infections

United States, Puerto Rico, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

HIV Infections

Uganda, United States, Kenya, Tanzania
National Institute of Allergy and Infectious Diseases...

Completed

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV

HIV Infections
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda

HIV Infections

Uganda
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

HIV Infections

United States

3

Subscribe